HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.7%

Neg 0% Neu 87.7% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.